Bromoacetone appears as a clear colorless liquid turning violet on standing, even in the absence of air, and decomposing to a black resinous mass on long standing. Denser than water and poorly soluble in water. Hence sinks in water. A violent lachrymator--low concentrations are very irritating to the eyes; high concentrations or prolonged exposure at lower concentrations may have adverse health effects. Very toxic by inhalation. Contact with the liquid causes painful burns. Used as a chemical war gas.
颜色/状态:
Colorless liquid; rapidly becomes violet even in absence of air
... In this study, the factors influencing the disposition and biotransformation of 1-bromopropane (1-BrP) were examined in male F344 rats and B6C3F1 mice following inhalation exposure (800 ppm) or intravenous administration (5, 20, and 100 mg/kg). (1,2,3-13C)1-BrP and (1-14C)1-BrP were administered to enable characterization of urinary metabolites using NMR spectroscopy, LC-MS/MS, and HPLC coupled radiochromatography. ... The molar ratio of exhaled 14CO2 to total released bromide, which decreased as dose increased, demonstrated that the proportion of 1-BrP metabolized via oxidation relative to pathways dependent on glutathione conjugation is inversely proportional to dose in the rat. (14C)1-BrP equivalents were recovered in urine (13-17%, rats; 14-23% mice), feces (< 2%), or retained in the tissues and carcass (< 6%) of rats and mice administered iv 5 to 100 mg/kg (14C)1-BrP. Metabolites characterized in urine of rats and mice include N-acetyl-S-propylcysteine, N-acetyl-3-(propylsulfinyl)alanine, N-acetyl-S-(2-hydroxypropyl)cysteine, 1-bromo-2-hydroxypropane-O-glucuronide, N-acetyl-S-(2-oxopropyl)cysteine, and N-acetyl-3-[(2-oxopropyl)sulfinyl]alanine. These metabolites may be formed following oxidation of 1-bromopropane to 1-bromo-2-propanol and bromoacetone and following subsequent glutathione conjugation with either of these compounds ...
Bromoacetone is a metabolic byproduct of bromopropane. It can react with glutathione and generate conjugates that are subsequently secreted in the urine.
Organobromide compounds such as bromoacetone are strong alkylating agents. Consequently they can readily modify free thiols (cysteines) and methionine residues of the surfaces of proteins leading to the disruption of enzyme, transporter or membrane functions. One of the most probable protein targets is the TRPA1 ion channel that is expressed in sensory nerves (trigeminal nerve) of the eyes, nose, mouth and lungs.
来源:Toxin and Toxin Target Database (T3DB)
毒理性
致癌物分类
无致癌性迹象(未被国际癌症研究机构列名)。
No indication of carcinogenicity (not listed by IARC). (L135)
A strong lachrymator. Inhalation, ingestion or skin contact with material may cause severe injury or death. Animal studies indicate that at very high concentrations it can cause kidney and liver damage. Bromoacetone causes ocular irritation in 30% of human subjects at 0.1 ppm and 100% of human subjects at 1.0 ppm.
来源:Toxin and Toxin Target Database (T3DB)
毒理性
暴露途径
该物质可以通过吸入其蒸气和摄入的方式被身体吸收。
The substance can be absorbed into the body by inhalation of its vapour and by ingestion.
来源:ILO-WHO International Chemical Safety Cards (ICSCs)
[EN] CRBN LIGANDS AND USES THEREOF<br/>[FR] LIGANDS CRBN ET LEURS UTILISATIONS
申请人:KYMERA THERAPEUTICS INC
公开号:WO2019140387A1
公开(公告)日:2019-07-18
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of CRBN, and the treatment of CRBN-mediated disorders.
本发明提供了化合物、其组合物以及使用这些化合物抑制CRBN并治疗CRBN介导的疾病的方法。
Guanidinium Ylide Mediated Aziridination from Arylaldehydes: Scope and Limitations in the Formation of Unactivated 3-Arylaziridine-2-carboxylates
Abstract The scope and limitations of guanidiniumylide mediated aziridinations from arylaldehydes yielding unactivated 3-arylaziridine-2-carboxylates, applicable to asymmetric synthesis, are discussed. The scope and limitations of guanidiniumylide mediated aziridinations from arylaldehydes yielding unactivated 3-arylaziridine-2-carboxylates, applicable to asymmetric synthesis, are discussed.
Provided are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases associated with or characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).
New quinoline- and isoquinoline-based multicomponent methods for the synthesis of 1,1(3,3)-dicyanotetrahydrobenzoindolizines
作者:I. A. Sanin、A. A. Zubarev、A. Yu. Rudenko、L. A. Rodinovskaya、E. A. Batuev、A. M. Shestopalov
DOI:10.1007/s11172-018-2073-z
日期:2018.2
multicomponent methods for the synthesis of benzannulated dihydroindolizines based on quinoline or isoquinoline, malononitrile, aromatic aldehydes and α-halomethylcarbonyl compounds were developed. Several alternative protocols of using the reactants were studied, starting with separate generation of two most probable intermediates and ending with the four-componentcondensation of all reactants. The scope